Reports Q1 revenue $321,000, consensus $291.670. As of March 31 cash, cash equivalents and investments were $8.4M compared to cash, cash equivalents and investments of $12.0M at December 31, 2024. “Our primary focus continues to be initiating the Phase 3 trial of larsucosterol for severe AH, contingent on securing sufficient funding,” stated James E. Brown, President and CEO of DURECT (DRRX). “We continue to be engaged in active dialogue to explore all options for funding the continued development of larsucosterol, including potential business development and financing transactions. Additionally, the publication of the results of our Phase 2b AHFIRM trial in January in NEJM Evidence provides important validation of the potential value of larsucosterol as a treatment for AH and supports our planned Phase 3 trial design.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRRX:
- DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential
- DURECT Corporation Reports 2024 Financial Results and Updates
- Durect reports Q4 cont ops EPS (6c), consensus (2c)
- Options Volatility and Implied Earnings Moves Today, March 26, 2025
- Options Volatility and Implied Earnings Moves This Week, March 24 – March 27, 2025
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue